

Alterations of DNA methylation and histone modification hepatocellular carcinomas

Hepatology Research

37, 974-983

DOI: [10.1111/j.1872-034x.2007.00141.x](https://doi.org/10.1111/j.1872-034x.2007.00141.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular pathogenesis of hepatocellular carcinoma. <i>Liver International</i> , 2008, 28, 160-174.	1.9	134
2	Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells. <i>PLoS ONE</i> , 2008, 3, e2037.	1.1	215
3	High-dimensional biology to comprehend hepatocellular carcinoma. <i>Expert Review of Proteomics</i> , 2008, 5, 45-60.	1.3	23
4	Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. <i>Carcinogenesis</i> , 2008, 29, 1901-1910.	1.3	114
5	An overview of hepatocellular carcinoma study by omics-based methods. <i>Acta Biochimica Et Biophysica Sinica</i> , 2009, 41, 1-15.	0.9	51
6	Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2009, 125, 388-397.	2.3	101
7	Aberrant DNA methylation profile and frequent methylation of <i>KLK10</i> and <i>OXGR1</i> genes in hepatocellular carcinoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 1057-1068.	1.5	32
8	Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer This paper is one of a selection of papers published in this Special Issue, entitled The 30th Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal's usual peer review process. <i>Biochemistry and Cell Biology</i> , 2009, 87, 711-746.	0.9	70
9	Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma. <i>Cancer Research</i> , 2009, 69, 9073-9082.	0.4	116
10	Epigenetic approaches to cancer therapy. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2009, 6, 71-79.	0.5	8
11	Epigenetic Targets in Cancer Epidemiology. <i>Methods in Molecular Biology</i> , 2009, 471, 457-467.	0.4	10
12	Effects of Mixtures of Polychlorinated Biphenyls, Methylmercury, and Organochlorine Pesticides on Hepatic DNA Methylation in Prepubertal Female Sprague-Dawley Rats. <i>International Journal of Toxicology</i> , 2009, 28, 294-307.	0.6	97
13	Transcriptional and post-transcriptional control of DNA methyltransferase 3B is regulated by phosphatidylinositol 3 kinase/Akt pathway in human hepatocellular carcinoma cell lines. <i>Journal of Cellular Biochemistry</i> , 2010, 111, 158-167.	1.2	21
14	Epigenetic cancer therapy: Proof of concept and remaining challenges. <i>BioEssays</i> , 2010, 32, 949-957.	1.2	67
15	Epigenetic modifications and human disease. <i>Nature Biotechnology</i> , 2010, 28, 1057-1068.	9.4	2,328
16	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	1.8	267
17	H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM. <i>Cancer Research</i> , 2010, 70, 7830-7840.	0.4	327
18	Modulation of gene expression in ovarian cancer by active and repressive histone marks. <i>Epigenomics</i> , 2010, 2, 39-51.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Xenoestrogen-Induced Regulation of EZH2 and Histone Methylation via Estrogen Receptor Signaling to PI3K/AKT. <i>Molecular Endocrinology</i> , 2010, 24, 993-1006.	3.7	156
20	Histone Modification Therapy of Cancer. <i>Advances in Genetics</i> , 2010, 70, 341-386.	0.8	63
21	Molecular approaches to treatment of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S264-S272.	0.4	75
22	DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. <i>Epigenomics</i> , 2010, 2, 467-481.	1.0	33
23	Epigenetics in cancer. <i>Carcinogenesis</i> , 2010, 31, 27-36.	1.3	2,119
24	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. <i>Nature Chemical Biology</i> , 2011, 7, 566-574.	3.9	465
25	Diagnostic and Prognostic Molecular Markers in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2011, 31, 181-190.	0.6	67
26	Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia. <i>PLoS ONE</i> , 2011, 6, e22110.	1.1	97
27	Histone onco-modifications. <i>Oncogene</i> , 2011, 30, 3391-3403.	2.6	261
28	Histone lysine methylation and demethylation pathways in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1815, 75-89.	3.3	214
29	From bench to bedside: Targeting epigenetics for cancer therapy. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 191-201.	0.1	1
30	Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6139-6150.	2.9	127
31	Epigenetic aberrations during oncogenesis. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 1681-1702.	2.4	156
32	Structure and Function of Histone H3 Lysine 9 Methyltransferases and Demethylases. <i>ChemBioChem</i> , 2011, 12, 254-263.	1.3	75
33	Progesterone Receptor Isoform-Specific Promoter Methylation: Association of <i>PRA</i> Promoter Methylation with Worse Outcome in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 4177-4186.	3.2	47
34	Hepatic ontogeny and tissue distribution of mRNAs of epigenetic modifiers in mice using RNA-sequencing. <i>Epigenetics</i> , 2012, 7, 914-929.	1.3	31
35	Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. <i>Gut</i> , 2012, 61, 392-401.	6.1	55
36	Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. <i>Molecular Biology International</i> , 2012, 2012, 1-8.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Integrative Array-Based Approach Identifies MZB1 as a Frequently Methylated Putative Tumor Suppressor in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 3541-3551.	3.2	25
38	Epigenetic Deregulation of MicroRNAs: New Opportunities to Target Oncogenic Signaling Pathways in Hepatocellular Carcinoma. <i>Current Pharmaceutical Design</i> , 2012, 19, 1192-1200.	0.9	11
39	Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. <i>Carcinogenesis</i> , 2012, 33, 1277-1285.	1.3	57
40	G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of Glucocorticoid Receptor target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19673-19678.	3.3	119
41	Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. <i>BMC Cancer</i> , 2012, 12, 386.	1.1	41
42	Oncoepigenomics: Making histone lysine methylation count. <i>European Journal of Medicinal Chemistry</i> , 2012, 56, 179-194.	2.6	16
43	Alterations of Histone Modifications in Cancer. , 2012, , 53-87.		5
44	Current limitations and future opportunities for epigenetic therapies. <i>Future Medicinal Chemistry</i> , 2012, 4, 425-446.	1.1	38
46	Epigenética e doenças humanas. <i>Semina: Ciências Biológicas E Da Saúde</i> , 2012, 33, .	0.0	2
47	Genome-wide DNA methylation profiles in hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1799-1808.	3.6	178
48	Comprehensive Epigenetic Analysis Using Oral Rinse Samples: A Pilot Study. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 1486-1494.	0.5	19
49	Long-term arsenic exposure induces histone H3 Lys9 dimethylation without altering DNA methylation in the promoter region of p16 ^{INK4a} and down-regulates its expression in the liver of mice. <i>Journal of Applied Toxicology</i> , 2013, 33, 951-958.	1.4	32
50	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	4.3	88
51	Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8931-8942.	2.9	220
52	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
53	Epigenetic Regulation of Autophagy by the Methyltransferase G9a. <i>Molecular and Cellular Biology</i> , 2013, 33, 3983-3993.	1.1	177
54	Cellular reprogramming and cancer development. <i>International Journal of Cancer</i> , 2013, 132, 1240-1248.	2.3	38
55	Nucleosome Occupancy and Gene Regulation During Tumorigenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 109-134.	0.8	7

#	ARTICLE	IF	CITATIONS
56	Expression Profiling of Hepatocellular Carcinoma. , 2013, , 163-184.		0
57	Histone Methylation Keeps the Brakes on Autophagy. <i>Molecular and Cellular Biology</i> , 2013, 33, 3974-3975.	1.1	11
58	Shortâ€Form CDYLb but not longâ€Form CDYLâ functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 644-655.	1.5	29
59	Inhibition of H3K9 methyltransferases G9a/GLP prevents ototoxicity and ongoing hair cell death. <i>Cell Death and Disease</i> , 2013, 4, e506-e506.	2.7	47
60	EPIGENETIC MECHANISMS IN HEPATITIS C VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA: A POTENTIAL NEW LINK BETWEEN STEM CELLS, VIROLOGY AND CANCER. <i>American Medical Journal</i> , 2013, 4, 21-35.	1.0	5
61	Regulation and Role of EZH2 in Cancer. <i>Cancer Research and Treatment</i> , 2014, 46, 209-222.	1.3	243
62	Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294. <i>Oncology Letters</i> , 2014, 7, 1819-1825.	0.8	12
63	The functional diversity of protein lysine methylation. <i>Molecular Systems Biology</i> , 2014, 10, 724.	3.2	202
64	Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: Potential targets for cancer control. <i>Toxicology and Applied Pharmacology</i> , 2014, 280, 296-304.	1.3	20
65	Lysine methylation in cancer: SMYD3â€MAP3K2 teaches us new lessons in the Rasâ€ERK pathway. <i>BioEssays</i> , 2014, 36, 1162-1169.	1.2	30
66	Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma. <i>Molecular Cancer</i> , 2014, 13, 172.	7.9	58
67	The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. <i>Molecular Cancer</i> , 2014, 13, 189.	7.9	127
68	Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 205-209.	1.3	152
69	Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation. <i>Leukemia Research</i> , 2014, 38, 822-829.	0.4	25
70	Design and synthesis of peptide-MCA substrates for a novel assay of histone methyltransferases and their inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1268-1275.	1.4	12
71	Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. <i>Cancer Letters</i> , 2014, 342, 223-230.	3.2	161
72	Epigenetic regulation of Progesterone Receptor isoforms: From classical models to the sexual brain. <i>Molecular and Cellular Endocrinology</i> , 2014, 392, 115-124.	1.6	9
73	A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenaseâ€2 in idiopathic pulmonary fibrosis. <i>FASEB Journal</i> , 2014, 28, 3183-3196.	0.2	87

#	ARTICLE	IF	CITATIONS
74	Alterations of epigenetics and microRNA in hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 31-42.	1.8	42
75	Context-specific regulation of cancer epigenomes by histone and transcription factor methylation. <i>Oncogene</i> , 2014, 33, 1207-1217.	2.6	26
76	DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells. <i>Oncology Letters</i> , 2015, 9, 2499-2506.	0.8	6
77	The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for C9a/GLP in the Epigenetics of Leukemia. <i>PLoS ONE</i> , 2015, 10, e0131716.	1.1	65
78	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 1.	0.9	25
79	Identification of Sites on Histone Modification of Cancer Cell. <i>Chinese Medical Sciences Journal</i> , 2015, 30, 203-209.	0.2	2
80	Chemical Probes of Histone Lysine Methyltransferases. <i>ACS Chemical Biology</i> , 2015, 10, 40-50.	1.6	46
81	Selective Inhibitors of Protein Methyltransferases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1596-1629.	2.9	112
82	Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. <i>Cancer Prevention Research</i> , 2015, 8, 702-711.	0.7	47
83	Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential. <i>Future Medicinal Chemistry</i> , 2015, 7, 2243-2261.	1.1	11
84	Global histone modifications in Fumonisin B1 exposure in rat kidney epithelial cells. <i>Toxicology in Vitro</i> , 2015, 29, 1809-1815.	1.1	26
85	OMICS technologies and their role in foregut primary malignancies. <i>Current Problems in Surgery</i> , 2015, 52, 409-441.	0.6	7
86	Epigenetic therapy as a novel approach in hepatocellular carcinoma. , 2015, 145, 103-119.		59
87	Predictive modelling of gene expression from transcriptional regulatory elements. <i>Briefings in Bioinformatics</i> , 2015, 16, 616-628.	3.2	33
88	Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2016, 2016, 1-13.	0.9	14
89	Toxicology and Epigenetics. , 2016, , 555-583.		0
90	Genome-wide genetic screen identified the link between dG9a and epidermal growth factor receptor signaling pathway in vivo. <i>Experimental Cell Research</i> , 2016, 346, 53-64.	1.2	4
91	Depletion of C9a gene induces cell apoptosis in human gastric carcinoma. <i>Oncology Reports</i> , 2016, 35, 3041-3049.	1.2	22

#	ARTICLE	IF	CITATIONS
92	Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. <i>Journal of Hematology and Oncology</i> , 2016, 9, 49.	6.9	124
94	Clinical Epigenetics and Epigenomics. <i>Translational Bioinformatics</i> , 2016, , 269-293.	0.0	0
95	Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. <i>Hepatology Research</i> , 2016, 46, 50-57.	1.8	54
96	Differential Expression of SWI/SNF Chromatin Remodeler Subunits Brahma and Brahma-Related Gene During Drug-Induced Liver Injury and Regeneration in Mouse Model. <i>DNA and Cell Biology</i> , 2016, 35, 373-384.	0.9	11
97	Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 6102-6108.	1.4	24
98	SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation. <i>Cancer Research</i> , 2016, 76, 6043-6053.	0.4	48
99	Integrating Epigenomics into the Understanding of Biomedical Insight. <i>Bioinformatics and Biology Insights</i> , 2016, 10, BBI.S38427.	1.0	22
100	Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development. <i>Cancer Cell</i> , 2016, 29, 354-366.	7.7	106
101	Recent advances in mass spectrometry analysis of histone post-translational modifications: potential clinical impact of the PAT-H-MS approach. <i>Expert Review of Proteomics</i> , 2016, 13, 245-250.	1.3	3
102	Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1876-1891.	2.9	54
103	Epigenetics in cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 29.	7.9	296
104	Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity. <i>MedChemComm</i> , 2017, 8, 1069-1092.	3.5	24
105	Misregulation of Histone Methylation Regulators in Cancer. <i>Cancer Drug Discovery and Development</i> , 2017, , 221-248.	0.2	2
106	Review of cancer from perspective of molecular. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 127-129.	0.2	352
107	Notch3 is frequently downregulated in oral cancer. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2017, 29, 504-510.	0.2	3
108	Inhibitors of Epigenetic Regulation in Cancer. , 2017, , 281-307.		1
109	Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. <i>Diseases (Basel)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 T	1.0	54
110	Potential Molecular Targets and Drugs for Treatment of Hepatocellular Carcinoma. <i>Journal of Cancer Science & Therapy</i> , 2017, 9, .	1.7	3

#	ARTICLE	IF	CITATIONS
111	Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 36354-36367.	0.8	40
112	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 591-602.	1.9	71
113	Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 449-460.	1.4	39
114	G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. <i>Theranostics</i> , 2018, 8, 2884-2895.	4.6	24
115	Target Identification Using Chemical Probes. <i>Methods in Enzymology</i> , 2018, 610, 27-58.	0.4	9
116	Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening. <i>Journal of Computer-Aided Molecular Design</i> , 2018, 32, 917-928.	1.3	12
117	Epigenetic Factors: Key Regulators Targeted in Cancers. , 0, , .		1
118	Alterations of Histone Modifications in Cancer. , 2018, , 141-217.		10
119	NASP antagonize chromatin accessibility through maintaining histone H3K9me1 in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3438-3448.	1.8	14
120	Increased expression of G9A contributes to carcinogenesis and indicates poor prognosis in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 9757-9765.	0.8	12
121	Clinicopathological significance of G9A expression in colorectal carcinoma. <i>Oncology Letters</i> , 2018, 15, 8611-8619.	0.8	11
122	High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors. <i>Scientific Reports</i> , 2018, 8, 12331.	1.6	4
123	Quinazolines as inhibitors of chromatin-associated proteins in histones. <i>Medicinal Chemistry Research</i> , 2019, 28, 395-416.	1.1	3
124	Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2516-2524.	1.0	2
125	Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2666-2689.	2.9	33
127	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. <i>Genes and Immunity</i> , 2019, 20, 1-9.	2.2	13
128	Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127475.	1.0	14
129	Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115379.	1.4	5

#	ARTICLE	IF	CITATIONS
130	EZH2-Targeted Therapies in Cancer: Hype or a Reality. <i>Cancer Research</i> , 2020, 80, 5449-5458.	0.4	139
131	Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy. <i>Theranostics</i> , 2020, 10, 10245-10261.	4.6	31
132	Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 605386.	1.3	44
133	Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 818.	1.3	14
134	Cell-free circulating epimarks in cancer monitoring. <i>Epigenomics</i> , 2020, 12, 145-155.	1.0	8
135	Epigenetic Control of a Local Chromatin Landscape. <i>International Journal of Molecular Sciences</i> , 2020, 21, 943.	1.8	15
136	G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. <i>Theranostics</i> , 2020, 10, 4515-4529.	4.6	27
137	Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122. <i>Cancers</i> , 2021, 13, 2376.	1.7	12
138	Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). <i>Frontiers in Oncology</i> , 2021, 11, 677926.	1.3	30
139	Detection of Epigenetic Aberrations in the Development of Hepatocellular Carcinoma. <i>Methods in Molecular Biology</i> , 2015, 1238, 709-731.	0.4	20
140	Molecular epigenetic targets for liver diseases: current challenges and future prospects. <i>Drug Discovery Today</i> , 2017, 22, 1620-1636.	3.2	7
141	Histone Methylation and the Initiation of Cancer. , 2008, , 109-150.		9
142	Novel Function of Lysine Methyltransferase G9a in the Regulation of Sox2 Protein Stability. <i>PLoS ONE</i> , 2015, 10, e0141118.	1.1	12
143	Down-Regulation of TSLP After EZH2 Silencing in ESCC Cell Line. <i>Journal of Biomedicine</i> , 2016, 1, .	0.0	1
144	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. <i>Oncotarget</i> , 2016, 7, 85624-85640.	0.8	44
145	Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 81571-81587.	0.8	37
146	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 21315-21326.	0.8	39
147	Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention. <i>Current Cancer Drug Targets</i> , 2013, 13, 558-579.	0.8	65

#	ARTICLE	IF	CITATIONS
148	Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code. <i>Current Chemical Genomics</i> , 2011, 5, 72-84.	2.0	52
149	DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: A case-control study. <i>World Journal of Gastroenterology</i> , 2007, 13, 6082.	1.4	27
150	Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein. <i>BMB Reports</i> , 2020, 53, 576-581.	1.1	12
151	Diagnosing Cancer Using Histone Modification Analysis. , 2008, , 347-357.		0
152	Role of DNA Methylation in Cancer Progression. , 2008, , 79-93.		0
153	Molecular Pathogenesis of Hepatocellular Carcinoma. , 2010, , 373-396.		0
154	Premalignant Hepatocellular Lesions. , 2011, , 457-472.		0
155	Biomarkers of Hepatocellular Carcinoma. , 2012, , 79-154.		0
156	The Fundamental Role of Epigenetic Regulation in Normal and Disturbed Cell Growth, Differentiation, and Stemness. , 2014, , 1-41.		0
158	Mass Spectrometry for the Identification of Posttranslational Modifications in Histones and Its Application in Clinical Epigenetics. , 2016, , 195-214.		1
159	Aberrant Epigenomic Regulatory Networks in Multiple Myeloma and Strategies for Their Targeted Reversal. <i>RNA Technologies</i> , 2019, , 543-572.	0.2	0
161	Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. <i>Cell Metabolism</i> , 2021, 33, 2247-2259.e6.	7.2	63
163	The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients. <i>Iranian Journal of Medical Sciences</i> , 2014, 39, 268-74.	0.3	8
164	Histone-modifying genes as biomarkers in hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 2496-507.	0.5	31
165	Diverse involvement of EZH2 in cancer epigenetics. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 175-93.	0.0	90
166	The Effect of 5-Aza-2'-Deoxycytidine in Combination to and in Comparison with Vorinostat on DNA Methyltransferases, Histone Deacetylase 1, Glutathione S-Transferase 1 and Suppressor of Cytokine Signaling 1 Genes Expression, Cell Growth Inhibition and Apoptotic Induction in Hepatocellular LCL-PI 1J Cell Line. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> . 2020. 14. 45-55.	0.3	6
167	A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer. <i>Current Drug Targets</i> , 2022, 23, 836-853.	1.0	7
168	BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes. <i>Biochemical and Biophysical Research Communications</i> , 2022, 590, 169-176.	1.0	2

#	ARTICLE	IF	CITATIONS
169	Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. <i>Cells</i> , 2021, 10, 3463.	1.8	6
170	Cyclobutanes in Small-Molecule Drug Candidates. <i>ChemMedChem</i> , 2022, 17, .	1.6	59
176	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
179	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. <i>Bioscience Reports</i> , 0, , .	1.1	2
180	ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner. <i>Science Advances</i> , 2022, 8, .	4.7	6
181	Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview. <i>Clinical and Translational Oncology</i> , 2023, 25, 1594-1605.	1.2	3
182	Characterizing crosstalk in epigenetic signaling to understand disease physiology. <i>Biochemical Journal</i> , 2023, 480, 57-85.	1.7	4
183	Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4059-4085.	2.9	5